Alliqua BioMedical, Inc. (NASDAQ:ALQA)’s share price fell 5.9% during mid-day trading on Tuesday . The stock traded as low as $0.31 and last traded at $0.32. Approximately 787,064 shares were traded during trading, an increase of 39% from the average daily volume of 566,056 shares. The stock had previously closed at $0.34.

Several research firms recently commented on ALQA. Zacks Investment Research raised shares of Alliqua BioMedical from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a research note on Tuesday, August 15th. HC Wainwright set a $2.00 price objective on shares of Alliqua BioMedical and gave the company a “buy” rating in a research report on Thursday, May 11th. Finally, ValuEngine downgraded shares of Alliqua BioMedical from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Alliqua BioMedical has an average rating of “Hold” and a consensus price target of $1.31.

The stock’s market capitalization is $15.41 million. The stock has a 50 day moving average of $0.33 and a 200-day moving average of $0.42.

Alliqua BioMedical (NASDAQ:ALQA) last released its earnings results on Thursday, August 10th. The company reported ($0.09) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.05. The firm had revenue of $5.52 million for the quarter, compared to analyst estimates of $5.01 million. Alliqua BioMedical had a negative net margin of 185.30% and a negative return on equity of 107.24%. The business’s quarterly revenue was up 23.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.22) earnings per share. Equities research analysts expect that Alliqua BioMedical, Inc. will post ($0.44) earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of ALQA. Renaissance Technologies LLC lifted its holdings in Alliqua BioMedical by 54.2% in the first quarter. Renaissance Technologies LLC now owns 632,800 shares of the company’s stock valued at $319,000 after acquiring an additional 222,400 shares during the period. KCG Holdings Inc. increased its position in Alliqua BioMedical by 777.7% during the 1st quarter. KCG Holdings Inc. now owns 525,077 shares of the company’s stock worth $265,000 after purchasing an additional 465,256 shares in the last quarter. Sabby Management LLC increased its position in Alliqua BioMedical by 93.7% during the 1st quarter. Sabby Management LLC now owns 2,131,050 shares of the company’s stock worth $1,076,000 after purchasing an additional 1,030,652 shares in the last quarter. Finally, Perceptive Advisors LLC increased its position in Alliqua BioMedical by 120.3% during the 1st quarter. Perceptive Advisors LLC now owns 4,233,951 shares of the company’s stock worth $2,136,000 after purchasing an additional 2,312,000 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/09/07/alliqua-biomedical-inc-alqa-trading-down-5-9-2.html.

Alliqua BioMedical Company Profile

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.